anv419
Recombinant proteinexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 25, 2021 (NCT04855929)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2AGONIST
IL2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05869539 | Phase 1 | Jun 21, 2023 | Anaveon AG, University of Basel |
| NCT05641324 | Phase 1 | Jan 31, 2023 | Anaveon AG |
| NCT05578872 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2022 | Anaveon AG |
| NCT04855929 | Phase 1/Phase 2 (Phase 2) | May 25, 2021 | Anaveon AG |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anaveon AG | For profit | 4 | 3 | 2 | 2021 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1